Syndeio Biosciences

Syndeio Biosciences (from the Ancient Greek word “to connect”) is a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in CNS disorders. The company’s proprietary Boost™ Synapse Pharmacology Platform combines electrophysiology, behavior, and human neuronal network assays to predict clinical outcomes with unprecedented accuracy. Syndeio’s clinical pipeline includes lead asset, zelquistinel, currently in Phase 2 development for major depressive disorder and will soon be entering an industry-first biomarker study in Alzheimer’s disease, and apimostinel, currently in an investigator-led phase 2 study for acute depression. The company is headquartered in Indianapolis, IN with research laboratories in Menlo Park, CA & Evanston, IL focused on advancing the Boost™ Synapse Pharmacology Platform.